ARDT Ardent Health, Inc.
Price Chart
Executive Summary
Ardent Health appointed COO Dave Caspers as President and CEO, succeeding Marty Bonick who stepped down effective June 2, 2026. Caspers received a new employment agreement with a $900,000 base salary, 105% target bonus, and equity grants totaling $3M in grant-date fair value ($1.05M RSUs + $1.95M performance-based RSUs). The company reaffirmed full-year 2026 Adjusted EBITDA guidance of $485-$535M but disclosed Q2 volume softness, which is a negative signal that tempers the otherwise routine leadership transition.
Actionable Insight
The Q2 volume softness disclosure is the key negative signal — watch for Q2 earnings in August for magnitude of the miss and whether the IMPACT program can offset. The CEO transition from an internal COO with operational focus is neutral-to-slightly-positive for execution, but the volume headwind is the dominant near-term factor.
Key Facts
- Dave Caspers appointed President and CEO effective June 2, 2026, succeeding Marty Bonick who stepped down
- Caspers' annual base salary set at $900,000 with target bonus of 105% of base salary for 2026
- One-time equity grants: $1,050,000 in time-based RSUs (3-year vesting) and $1,950,000 target in performance-based RSUs (2026 performance period, vesting April 2029)
- Full-year 2026 Adjusted EBITDA guidance reaffirmed at $485-$535 million
- CFO disclosed Q2 volume softness across portfolio, with IMPACT program accelerated and expanded in response
- Caspers has 24-month post-employment non-compete and non-solicitation covenants
- Severance: 2x salary + target bonus for non-CIC termination; 3x for termination within 6 months before to 18 months after Change in Control
Financial Impact
CEO transition with $3M in new equity grants; reaffirmed $485-$535M FY2026 Adjusted EBITDA guidance; Q2 volume softness noted
Risk Factors
- Q2 volume softness could lead to FY2026 guidance reduction if it persists into H2
- CEO transition execution risk despite internal appointment
- Potential for further operational disruption from accelerated IMPACT restructuring program
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-253567 |
| Document: d854796d8k.htm | 0001193125-26-253567 |
| Document: d854796dex991.htm | 0001193125-26-253567 |
| Document: 0001193125-26-253567-index-headers.html | 0001193125-26-253567 |
| Document: 0001193125-26-253567-index.html | 0001193125-26-253567 |
| Document: 0001193125-26-253567.txt | 0001193125-26-253567 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
4d ago
|
8-K
| — | awaiting T+20 | — | — |
|
May 5, 2026
4w ago
|
8-K
| $9.37 $7.83 | ▼ −16.44% | ▼ −19.22% | $8.68 (−7.36%) |
|
Apr 8, 2026
8w ago
|
DEFA14A
| $9.53 $9.37 | ▼ −1.68% | ▼ −9.25% | $8.68 (−8.92%) |
|
Mar 4, 2026
13w ago
|
8-K
| $9.44 $8.66 | ▼ −8.26% | ▼ −4.47% | $8.68 (−8.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access